{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:29:41Z","timestamp":1788877781812,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bayer AG, Berlin, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, improves kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The FINE-REAL study (NCT05348733) aims to evaluate the characteristics and treatment patterns of participants treated with finerenone in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FINE-REAL is a prospective, single-arm, non-interventional study of patients initiated on finerenone as part of their routine care in accordance with country-approved labels. The study, initiated in June 2022, is expected to be completed by January 2028. The cutoff for this pre-specified interim analysis was June 13, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants were recruited across nephrology, endocrinology, cardiology, and primary care settings. Of 556 participants enrolled in the study by the cut-off date, 504 were included in this analysis (median follow-up duration of 7\u00a0months [finerenone treatment initiation to last recorded observation]). At baseline, 76.1% of participants were in the high or very high (KDIGO) CKD risk categories. Angiotensin converting enzyme inhibitors\/angiotensin receptor blockers and sodium\u2013glucose cotransporter 2 inhibitors were prescribed to 71.8% and 46.6% of participants, respectively. Based on prescribing information, 87.9% and 12.1% of participants initiated finerenone at doses of 10 and 20\u00a0mg, respectively. Finerenone treatment was uninterrupted in 92.3% of participants after 7\u00a0months\u2019 median follow-up. Treatment-emergent adverse events occurred in 110 (21.8%) participants. Hyperkalemia occurred in 25 (5.0%) participants, with no cases leading to death, dialysis, or hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>At this interim analysis, finerenone was initiated in patients with CKD and T2D across various clinical practices participating in the study. Treatment discontinuation and hyperkalemia occurred infrequently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-024-02070-y","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:01:54Z","timestamp":1727481714000},"page":"2223-2232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3535-9120","authenticated-orcid":false,"given":"Susanne B.","family":"Nicholas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar R.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D.","family":"Navaneethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Pantalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Fatoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Horvat-Broecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Garreta-Rufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"2070_CR1","unstructured":"IDF. IDF diabetes atlas. 2021. https:\/\/diabetesatlas.org\/. Accessed 3 May 2022."},{"issue":"1","key":"2070_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2015-000154","volume":"4","author":"B Wu","year":"2016","unstructured":"Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S et al (2016) Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007\u20132012. BMJ Open Diabetes Res Care 4(1):e000154. https:\/\/doi.org\/10.1136\/bmjdrc-2015-000154","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2070_CR3","unstructured":"ISN. ISN global kidney health atlas. 2023. https:\/\/www.theisn.org\/wp-content\/uploads\/media\/ISN%20Atlas_2023%20Digital_REV_2023_10_03.pdf. Accessed 23 November 2023."},{"issue":"5","key":"2070_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.xkme.2021.04.018","volume":"3","author":"J Hong","year":"2021","unstructured":"Hong J, Surapaneni A, Daya N, Selvin E, Coresh J, Grams ME et al (2021) Retinopathy and risk of kidney disease in persons with diabetes. Kidney Med 3(5):808-15e1. https:\/\/doi.org\/10.1016\/j.xkme.2021.04.018","journal-title":"Kidney Med"},{"key":"2070_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100739","volume":"32","author":"CA Lawson","year":"2021","unstructured":"Lawson CA, Seidu S, Zaccardi F, McCann G, Kadam UT, Davies MJ et al (2021) Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine 32:100739. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100739","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2070_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000513782","volume":"145","author":"K Folkerts","year":"2021","unstructured":"Folkerts K, Kelly AMB, Petruski-Ivleva N, Fried L, Blankenburg M, Gay A et al (2021) Cardiovascular and renal outcomes in patients with Type-2 diabetes and chronic kidney disease identified in a United States administrative claims database: a population cohort study. Nephron 145(4):342\u2013352. https:\/\/doi.org\/10.1159\/000513782","journal-title":"Nephron"},{"issue":"4","key":"2070_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000441582","volume":"40","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Joki N, Hase H (2015) Ischemic heart disease in patients with end-stage kidney disease. Blood Purif 40(4):332\u2013336. https:\/\/doi.org\/10.1159\/000441582","journal-title":"Blood Purif"},{"issue":"1","key":"2070_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12975-016-0499-x","volume":"8","author":"WL Lau","year":"2017","unstructured":"Lau WL, Huisa BN, Fisher M (2017) The cerebrovascular-chronic kidney disease connection: perspectives and mechanisms. Transl Stroke Res 8(1):67\u201376. https:\/\/doi.org\/10.1007\/s12975-016-0499-x","journal-title":"Transl Stroke Res"},{"issue":"5","key":"2070_CR9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). Kidney Int 102(5):974\u2013989","journal-title":"Kidney Int"},{"issue":"10","key":"2070_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","volume":"28","author":"L Blonde","year":"2022","unstructured":"Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M et al (2022) American Association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract 28(10):923\u20131049. https:\/\/doi.org\/10.1016\/j.eprac.2022.08.002","journal-title":"Endocr Pract"},{"issue":"39","key":"2070_CR11","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ et al (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44(39):4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"issue":"10365","key":"2070_CR12","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"issue":"10","key":"2070_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/s2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653\u2013662. https:\/\/doi.org\/10.1016\/s2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2070_CR14","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12(12):2032\u20132045. https:\/\/doi.org\/10.2215\/CJN.11491116","journal-title":"Clin J Am Soc Nephrol"},{"key":"2070_CR15","unstructured":"Bayer HealthCare Pharmaceuticals Inc. KERENDIA (finerenone) tablets, for oral use: US prescribing information. 2021. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Kerendia_PI.pdf. Accessed 26 June 2023."},{"key":"2070_CR16","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Kerendia summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kerendia-epar-product-information_en.pdf. Accessed 26 June 2023."},{"issue":"23","key":"2070_CR17","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"2070_CR18","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385:2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"issue":"6","key":"2070_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"issue":"Supplement_1","key":"2070_CR20","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.2337\/dc22-S011","volume":"45","author":"B Draznin","year":"2022","unstructured":"Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R et al (2022) 11 Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care 45(Supplement_1):S175\u2013S184. https:\/\/doi.org\/10.2337\/dc22-S011","journal-title":"Diabetes Care"},{"issue":"37","key":"2070_CR21","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2023) 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627\u20133639. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"2070_CR22","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0076","author":"D Vizcaya","year":"2023","unstructured":"Vizcaya D, Kovesdy CP, Reyes A, Pessina E, Pujol P, James G et al (2023) Characteristics of patients with chronic kidney disease and type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study. J Comp Eff Res. https:\/\/doi.org\/10.57264\/cer-2023-0076","journal-title":"J Comp Eff Res"},{"issue":"4","key":"2070_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108411","volume":"37","author":"NR Desai","year":"2023","unstructured":"Desai NR, Navaneethan SD, Nicholas SB, Pantalone KM, Wanner C, Hamacher S et al (2023) Design and rationale of FINE-REAL: a prospective study of finerenone in clinical practice. J Diabetes Complicat 37(4):108411. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108411","journal-title":"J Diabetes Complicat"},{"issue":"9","key":"2070_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"issue":"3","key":"2070_CR25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/dom.14915","volume":"25","author":"P Rossing","year":"2023","unstructured":"Rossing P, Garweg JG, Anker SD, Osonoi T, Pitt B, Rosas SE et al (2023) Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR\/DeFineDR). Diabetes Obes Metab 25(3):894\u2013898. https:\/\/doi.org\/10.1111\/dom.14915","journal-title":"Diabetes Obes Metab"},{"key":"2070_CR26","doi-asserted-by":"publisher","first-page":"215013272110036","DOI":"10.1177\/21501327211003683","volume":"12","author":"EA Christofides","year":"2021","unstructured":"Christofides EA, Desai N (2021) Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes mellitus: addressing the barriers to albuminuria testing. J Prim Care Community Health 12:21501327211003684. https:\/\/doi.org\/10.1177\/21501327211003683","journal-title":"J Prim Care Community Health"},{"issue":"1","key":"2070_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","volume":"99","author":"MG Shlipak","year":"2021","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V et al (2021) The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 99(1):34\u201347. https:\/\/doi.org\/10.1016\/j.kint.2020.10.012","journal-title":"Kidney Int"},{"issue":"4","key":"2070_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108418","volume":"37","author":"KM Pantalone","year":"2023","unstructured":"Pantalone KM, Ji X, Kong SX, Elliott JC, Milinovich A, Misra-Hebert AD et al (2023) Unmet needs and opportunities for optimal management of patients with type 2 diabetes and chronic kidney disease. J Diabetes Complicat 37(4):108418. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108418","journal-title":"J Diabetes Complicat"},{"issue":"8","key":"2070_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000024655","volume":"100","author":"B Yu","year":"2021","unstructured":"Yu B, Dong C, Hu Z, Liu B (2021) Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 100(8):e24655. https:\/\/doi.org\/10.1097\/md.0000000000024655","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"2070_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/circulationaha.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW et al (2022) Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with Type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145(8):575\u2013585. https:\/\/doi.org\/10.1161\/circulationaha.121.055459","journal-title":"Circulation"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02070-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02070-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02070-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:39Z","timestamp":1777564419000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/8\/2223\/8306357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02070-y","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"12 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is sponsored by Bayer AG. The authors wrote the article with the assistance of a medical writer funded by the sponsor. The sponsor was involved in the study design and the writing of the report. Susanne B. Nicholas is supported by NIH research grants R01MD014712, RF00250-2022-0038, U2CDK129496, P50MD017366, and CDC project number 75D301-21-P-12254; received research support from Bayer AG for the submitted work, as well as research support from Goldfinch Bio, Travere, and Terasaki Institute of Biomedical Innovation; and personal fees and other support from AstraZeneca, Bayer AG, Gilead, Novo Nordisk, and Boehringer Ingelheim\/Lilly. Ricardo Correa-Rotter has received consulting and\/or speaker and\/or advisory board fees and\/or research support from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, Novo Nordisk and Roche. Nihar Desai works under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures used for public reporting and pay for performance programs. He reports research grants and consulting for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, SCPharmaceuticals, and Vifor. Lixin Guo has nothing to disclose. Sankar D. Navaneethan reports receipt of personal fees from AstraZeneca (Data and Safety Monitoring Board), ACI clinical (Clinical Event Committee), Bayer, Boehringer Ingelheim\/Lilly, GSK, Intercept, Vifor, and Vertex; and grants from Keryx outside the submitted work. Kevin M. Pantalone discloses speaker bureau fees from AstraZeneca, Corcept Therapeutics, Merck, and Novo Nordisk; consulting fees from AstraZeneca, Bayer, Corcept Therapeutics, Diasome, Eli Lilly, Novo Nordisk, Merck, Sanofi, and Twinhealth; and research support from Bayer, Novo Nordisk, Merck, and Twinhealth. Christoph Wanner reports steering committee and advisory board participation as well as lecturing honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, FMC, Gilead, GSK, MSD, Sanofi, and Vifor. Stefanie Hamacher was an employee of ClinStat GmbH at the time of the study and reports consulting or advisory roles of her former CRO with Bayer AG. Samuel Fatoba is an employee of Bayer U.S. LLC, Pharmaceuticals. Andrea Horvat-Broecker is an employee of Bayer AG, Germany. Antonio Garreta-Rufas is an employee of Bayer AG, Germany. Alain Gay was an employee of Bayer AG, Germany at the time the interim analysis was performed. Martin Merz is an employee of Bayer AG, Germany. David C. Wheeler has received honoraria from Astellas, AstraZeneca (ongoing consultancy agreement), Amgen, Bayer, Boehringer Ingelheim, GSK, Gilead, Janssen, Mundipharma, Merck Sharp and Dohme, Tricida, Vifor, and Zydus.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Documented approval from appropriate independent ethics committees\/institutional review boards was obtained for all participating centers in applicable countries prior to study start. The study is being conducted within an approved drug indication in accordance with guidelines and regulations of the European Medicines Agency, the U.S. Food and Drug Administration [\n                      \n                      ,\n                      \n                      ], and applicable local laws and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Documented approval from appropriate independent ethics committees\/institutional review boards was obtained for all participating centers in applicable countries prior to study start. The study is being conducted within an approved drug indication in accordance with guidelines and regulations of the European Medicines Agency, the U.S. Food and Drug Administration, and applicable local laws and regulations. All participants provided written informed consent. This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"All participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}}]}}